New drug Rina-S shows promise in lung cancer trial

NCT ID NCT07288177

Recruiting now Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Dec 29, 2025 · Last updated Apr 28, 2026 · Updated 16 times

Summary

This study tests a new drug, Rina-S, in about 240 people with advanced non-small cell lung cancer that has worsened after other treatments. Everyone receives the active drug; no one gets a placebo. The goal is to see if Rina-S can shrink tumors and control the disease, with treatment continuing as long as it helps and side effects are manageable.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Astera Cancer Care
RECRUITING

East Brunswick, New Jersey, 08816, United States
Japan Community Health Care Organization Chukyo Hospital
RECRUITING

Nagoya, Minami Ward, Japan
Kyoto Prefectural University of Medicine
RECRUITING

Kyoto, Kyoto, Japan
NHO Kinki Chuo Chest Medical Center
RECRUITING

Sakai, Osaka, Japan
Nebraska Hematology-Oncology
RECRUITING

Lincoln, Nebraska, 68506, United States
ONE Onc: New York Oncology Hematology
RECRUITING

Albany, New York, 12206, United States
Providence Medical Foundation (St. Joseph Heritage Healthcare)
RECRUITING

Santa Rosa, California, 95403, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CANCER (NSCLC) NON-SMALL CELL LUNG CANCER (NSCLC)